Trial
NCT02892734
Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Northwestern University
Collaborators
Bristol-Myers Squibb; National Cancer Institute (NCI)
Condition
HER2/Neu Negative
Intervention
Ipilimumab
Why stopped
Slow accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-07-16